Sai Parenterals Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Sai Parenterals Ltd filed with BSE on 18 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Sai Parenterals reported Q1 FY'27 consolidated revenue of Rs. 182 crores with EBITDA of Rs. 27 crores at a 14.9% margin, and management attributed a sequential margin gain to price revision recovery lags unwinding, offset partly by air freight costs incurred in Australia due to disruption in shipments from the Indian contract manufacturing network. The Board approved redeploying Rs. 101.85 crores of IPO proceeds, originally earmarked for capacity upgradation and an R&D center, toward 60% stakes in Saicriti Pharma and Prathyak Laboratories, citing a Telangana government policy restricting upgradations within the outer ring road. Management reiterated full-year guidance of Rs. 750 crores revenue at approximately 17% EBITDA margin for FY'27, describing the year as weighted toward the second half.
Numbers mentioned
Consolidated total revenue: Rs. 182 crores (Q1 FY'27)
p. 3
“Consolidated total revenue for the quarter stood at Rs. 182 crores against Rs. 201 crores in the Q4 FY '26.”
Anil K K, page 3 of the filed PDF · View the filing
Gross profit: Rs. 76 crores (Q1 FY'27)
p. 3
“Gross profit was Rs. 76 crores at gross margin of 41.8%.”
Anil K K, page 3 of the filed PDF · View the filing
EBITDA: Rs. 27 crores (Q1 FY'27)
p. 3
“EBITDA stood at Rs. 27 crores at a margin of 14.9% and profit after tax at Rs. 8 crores at margin of 4.3%.”
Anil K K, page 3 of the filed PDF · View the filing
Gross margin: 41.8% (Q1 FY'27)
p. 3
“Gross margin improved to 41.8% from 38.1% in the preceding quarter, an expansion of 370 basis points.”
Anil K K, page 3 of the filed PDF · View the filing
Standalone total revenue: Rs. 56 crores (Q1 FY'27)
p. 8
“On a standalone basis, total revenue stood at Rs. 56 crores against Rs. 20 crores in Q1 of last year, a growth of 175%.”
Anil Kumar, page 8 of the filed PDF · View the filing
Standalone EBITDA margin: about 29% (Q1 FY'27)
p. 8
“EBITDA was at about Rs. 17 crores against Rs. 4 crores, a growth of more than 4 times at a margin of about 29% against 20% of previous year.”
Anil Kumar, page 8 of the filed PDF · View the filing
Debt: approximately Rs. 310 crores (as on 30th June 2026)
p. 8
“As on 30th June 2026, the debt stood at approximately about Rs. 310 crores as against March debt of about Rs. 319 crores, with cash and cash equivalent of about Rs. 184 crores.”
Anil Kumar, page 8 of the filed PDF · View the filing
Gross debt to equity ratio: 0.6 times (FY'27 peak)
p. 9
“Even at peak debt, the gross debt to equity ratio is comfortably placed at 0.6 times.”
Anil Kumar, page 9 of the filed PDF · View the filing
EBOS/TerryWhite Chemmart agreement value: AUD 202 million
p. 6
“The agreement as a whole is valued at AUD 202 million, or approximately Rs. 1,300 crore at $1 to Rs. 64.5.”
Mark Thulborne, page 6 of the filed PDF · View the filing
Saicriti acquisition amount: Rs. 83.83 crores
p. 4
“the company proposes to acquire 60% equity stake in Saicriti Pharma Private Limited, a newly established company for Rs. 83.83 crores.”
Anil K K, page 4 of the filed PDF · View the filing
Prathyak Laboratories acquisition amount: Rs. 15 crores
p. 5
“Our dedicated research and development subsidiary proposes to acquire a 60% equity in Prathyak Laboratories Private Limited for Rs. 15 crores while the quantum originally earmarked for a Greenfield research plant center was Rs. 18.02 crores.”
Anil K K, page 5 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue — Rs. 750 crores · FY '27
stated firmly by Anil K K
p. 5
“Let me close my remarks by recreating our guidance of Rs. 750 crores in revenue for FY '27 at an EBITDA margin of around 17%.”
Anil K K, page 5 of the filed PDF · View the filing
EBITDA margin — around 17% · FY '27
stated firmly by Anil K K
p. 5
“Let me close my remarks by recreating our guidance of Rs. 750 crores in revenue for FY '27 at an EBITDA margin of around 17%.”
Anil K K, page 5 of the filed PDF · View the filing
Australian facility completion — physical completion · January 2027
stated firmly by Anil K K
p. 5
“Construction is on schedule with physical completion targeted for January 2027.”
Anil K K, page 5 of the filed PDF · View the filing
TGA licensing inspection — 31st March 2027
stated firmly by Anil K K
p. 5
“The TGA licensing inspection anticipated by 31st March 2027 and Phase 1 manufacturing expected from April 2027.”
Anil K K, page 5 of the filed PDF · View the filing
Saicriti facility completion — April 2027
stated firmly by Anil K K
p. 5
“That is roughly 47% more capacity on a larger and long-lived asset, at an unchanged CAPEX outlet from the company and with the completion extended only about a month to April 2027.”
Anil K K, page 5 of the filed PDF · View the filing
Prathyak Laboratories transaction completion — on or before 30th September
stated firmly by Anil K K
p. 5
“The transaction is expected to complete on or before 30th September with Prathyak becoming a step-down subsidiary of the company and will be named as Sai Prathyak.”
Anil K K, page 5 of the filed PDF · View the filing
US market entry
stated as an aspiration by Anil K K
p. 5
“This evaluation is at a preliminary stage and we will make appropriate disclosures as and when there are developments to report.”
Anil K K, page 5 of the filed PDF · View the filing
Inventory levels at Australian facility — around 5-6 months' worth of inventory base
stated conditionally by Mark Thulborne
p. 8
“Local manufacturing removes this lead time and we expect inventory to ease to around 5-6 months' worth of inventory base.”
Mark Thulborne, page 8 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management clarified the new products are additional to the existing contract value.
Answered by Mark Thulborne
Asked by Vandit Dharamshi: Does the AUD 202 million order include the 12 new products to be developed annually, or are they additional?
p. 9
“No, these drugs will be up and above the value. The value that we have tabled is the existing value of the existing supply portfolio.”
Mark Thulborne, page 9 of the filed PDF · View the filing
Management confirmed further order wins are expected.
Answered by Mark Thulborne
Asked by Vandit Dharamshi: Should similar large order wins be expected over the next year?
p. 10
“Yes, there should. That is correct.”
Mark Thulborne, page 10 of the filed PDF · View the filing
Management explained a Telangana government order barred upgradation within the outer ring road, prompting the acquisition route instead.
Answered by Anil K K
Asked by Vanshi Shah: What is the strategic rationale for acquiring 60% of a new manufacturing entity rather than upgrading existing facilities?
p. 11
“So incidentally, they also enlightened us that we can't give any further permissions for the upgradations in these facilities because government has taken its firm decision of moving out red category and orange categories out of the outer ring road perspective that is outside the city.”
Anil K K, page 11 of the filed PDF · View the filing
Management said prior injectable output was mostly domestic and not export-qualified, and the company is now targeting export markets via the new EU-GMP facility.
Answered by Anil K K
Asked by Mohammed Nameer: What is driving the downward trend in injectable segment realization?
p. 13
“Currently, whatever the exports we are doing, the entire exports are only oral dosage formulations and Cephalosporins. Till now, we did not cater any of our injectable space into exports.”
Anil K K, page 13 of the filed PDF · View the filing
CFO said the elevated costs were one-time, related to supply constraints and additional freight and regulatory costs.
Answered by Anil Kumar
Asked by Mohammed Nameer: Is the Rs. 26 crore (later clarified as higher) other expense at Noumed a one-off?
p. 13
“So there was onetime hits in the last quarter because of constraints of supplies which we had to incur additional costs.”
Anil Kumar, page 13 of the filed PDF · View the filing
Management said it was too early to give an FY'28 number and would wait to see how the next quarters progress.
Answered by Anil K K
Asked by Arvind Arora: Is there any upward revision planned to FY'28 guidance?
p. 14
“Yes. 28, Arvind, we just not thought more on that because still we want to see how the 3 quarters goes in.”
Anil K K, page 14 of the filed PDF · View the filing
Management said the disruption-related costs are behind them and expects the guidance to be met comfortably.
Answered by Anil K K
Asked by Arvind Arora: Is the worst over in terms of margin pressure from this quarter onwards?
p. 14
“Now, I think next quarter, I don't think we will have the challenges coming in.”
Anil K K, page 14 of the filed PDF · View the filing
Management confirmed no related party connection exists as of the call date.
Answered by Anil K K
Asked by Devanshi Shah: Is Saicriti a related party?
p. 14
“No, it is not a related party. It was established by the promoters of Saicriti on their own.”
Anil K K, page 14 of the filed PDF · View the filing
Management said the plan is still under evaluation and not yet decided.
Answered by Anil K K
Asked by Mohit Oberoi: What is the precise strategy for the proposed US subsidiary?
p. 16
“Everything is under consideration, not yet decided everything.”
Anil K K, page 16 of the filed PDF · View the filing
CFO said current debt has declined slightly and additional debt will arise from the Saicriti acquisition, keeping debt-equity around 0.6.
Answered by Anil Kumar
Asked by Mohit Oberoi: What is expected peak debt level and the de-leveraging path?
p. 16
“But I would see that debt equity ratio should be in the range of 0.6%, which should be fairly well-placed for us.”
Anil Kumar, page 16 of the filed PDF · View the filing
Risks flagged
Disruption in West Asia delayed consignments from the Indian contract manufacturing network into the Australian market, requiring costlier air freight.
p. 4
“The situation in West Asia delayed consignments from the Indian contract manufacturing network into our Australian market.”
Anil K K, page 4 of the filed PDF · View the filing
Elevated air freight costs in Australia weighed on margins.
p. 4
“I would emphasize that this improvement was achieved on a lower revenue base, and it was achieved despite absorbing elevated air freight cost in Australia.”
Anil K K, page 4 of the filed PDF · View the filing
Physical site constraint at Jeedimetla prevents expansion of Unit-1 and Unit-2.
p. 4
“The Jeedimetla site measures approximately 3,100 square yards against the 12,000-13,000 square yards that EU-GMP injectable plant of this scale requires.”
Anil K K, page 4 of the filed PDF · View the filing
Regulatory change under Telangana's HILTP policy restricts upgradation within the outer ring road.
p. 4
“units situated within the outer ring road may convert that land and relocate outside it and materially for us, upgradations within the outer ring road are no longer permitted.”
Anil K K, page 4 of the filed PDF · View the filing
Long lead times of 9-10 months of mandatory inventory holding due to shipping lead times from India.
p. 8
“At this point in time, we are into a position of having to mandatorily hold 9-10 months' worth of inventory due to the 60-day, 90-day shipping lead times from India and other networks in our CMO criteria.”
Mark Thulborne, page 8 of the filed PDF · View the filing
Supply constraints led to additional freight and regulatory costs, reducing Noumed revenue in the quarter.
p. 13
“So based on those supply constraints, we had to incur additional costs on freight and regulatory costs.”
Anil Kumar, page 13 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.